Infliximab Paediatric Crohnʼs Disease Educational Plan-Reference-Cited by-同舟云学术

Infliximab Paediatric Crohnʼs Disease Educational Plan

Published:2010-06 Issue:6 Volume:33 Page:489-501
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Safety

Author:

Arana Alejandro,Allen Sam,Burkowitz Jörg,Fantoni Valerio,Ghatnekar Ola,Rico María Teresa,Vanhaverbeke Nathalie,Wentworth Charles E.,Brosa Max,Arellano Felix M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Reference29 articles.

1. Infectious complications of tumor necrosis factor blockade

2. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

3. The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel

4. Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of the golimumab educational program in ensuring healthcare professionals’ awareness of risks described in the European risk management plan;Therapeutic Advances in Drug Safety;2019-01

2. Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations;British Journal of Clinical Pharmacology;2017-12-20

3. The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products;Drug Safety;2017-12-07

4. Methodological gaps in the assessment of risk minimization interventions: a systematic review;Pharmacoepidemiology and Drug Safety;2014-02-24

5. Evaluating the effectiveness of risk minimisation;Therapeutic Risk Management of Medicines;2014